MENU
+Compare
GIFOF
Stock ticker: OTC
AS OF
Jun 20 closing price
Price
$8.81
Change
+$0.56 (+6.79%)
Capitalization
8.78B

GIFOF stock forecast, quote, news & analysis

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more

GIFOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GIFOF with price predictions
Jul 03, 2025

GIFOF's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for GIFOF turned positive on June 20, 2025. Looking at past instances where GIFOF's MACD turned positive, the stock continued to rise in of 34 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 38 cases where GIFOF's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.955) is normal, around the industry mean (5.632). P/E Ratio (48.309) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.386) is also within normal values, averaging (3.004). Dividend Yield (0.044) settles around the average of (0.161) among similar stocks. P/S Ratio (0.851) is also within normal values, averaging (3.643).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GIFOF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GIFOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

A.I.Advisor
published Dividends

GIFOF paid dividends on June 07, 2021

Grifols Sa GIFOF Stock Dividends
А dividend of $0.36 per share was paid with a record date of June 07, 2021, and an ex-dividend date of June 03, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 9%. PTKFF experienced the highest price growth at 24%, while CHGCF experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 72
Price Growth Rating: 54
SMR Rating: 58
Profit Risk Rating: 79
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
GIFOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Avinguda de la Generalitat, 152-158
Phone
+34 935710500
Employees
26314
Web
https://www.grifols.com